Landscape Capital Management L.L.C. Makes New $461,000 Investment in Becton, Dickinson and Company (NYSE:BDX)

Landscape Capital Management L.L.C. purchased a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,910 shares of the medical instruments supplier’s stock, valued at approximately $461,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Acadian Asset Management LLC grew its stake in shares of Becton, Dickinson and Company by 843.7% during the first quarter. Acadian Asset Management LLC now owns 3,237 shares of the medical instruments supplier’s stock worth $799,000 after buying an additional 2,894 shares during the last quarter. CreativeOne Wealth LLC bought a new stake in Becton, Dickinson and Company during the 1st quarter worth $297,000. Advisors Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 3.9% in the 1st quarter. Advisors Asset Management Inc. now owns 3,850 shares of the medical instruments supplier’s stock worth $953,000 after purchasing an additional 146 shares in the last quarter. Epoch Investment Partners Inc. boosted its stake in shares of Becton, Dickinson and Company by 1.2% during the first quarter. Epoch Investment Partners Inc. now owns 14,939 shares of the medical instruments supplier’s stock valued at $3,697,000 after purchasing an additional 184 shares in the last quarter. Finally, Lazard Asset Management LLC grew its holdings in shares of Becton, Dickinson and Company by 96,125.0% during the first quarter. Lazard Asset Management LLC now owns 3,849 shares of the medical instruments supplier’s stock worth $952,000 after purchasing an additional 3,845 shares during the last quarter. 86.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

BDX has been the subject of a number of research reports. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Raymond James cut their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $283.00.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $224.00 on Friday. The business has a 50-day moving average price of $235.15 and a two-hundred day moving average price of $234.54. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $249.89. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company has a market cap of $64.74 billion, a P/E ratio of 37.71, a PEG ratio of 1.68 and a beta of 0.43.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The business had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. During the same period in the previous year, the company posted $3.42 earnings per share. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a dividend of $1.04 per share. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.86%. Becton, Dickinson and Company’s dividend payout ratio is currently 63.97%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.